# Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct04270591/  
OnCo record `nct04270591` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Glumetinib in non-small-cell lung cancer, run by Haihe Biopharma Co., Ltd., now recruiting.

## Summary

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04270591 by Haihe Biopharma Co., Ltd., with 183 participants planned, started 2019-07-15 and due to reach its primary completion in 2023-10-25. Interventions recorded: Glumetinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04270591
- Phase: 1/2
- Setting: A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET-alterations
- Sponsor: Haihe Biopharma Co., Ltd.
- Enrolled: 183

## Sources

- ClinicalTrials.gov NCT04270591: https://clinicaltrials.gov/study/NCT04270591

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Glumetinib](https://onco.cc/drugs/glumetinib/)
- companies: [Haihe Biopharma](https://onco.cc/companies/haihe-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04270591.json